Study Explores Treatment Discontinuation Rates, Resource Utilization Among Patients With CLL/SLL
A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.
United States American Society Of Hematology Annual Meeting Hematology Annual Meeting Symphony Integrated Dataverse Btk Inhibitors
Source: ajmc.com